Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Brief description of study

Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Clinical Study Identifier: NCT03350815

Start Over

Novartis Investigative Site

Saint Clair Shores, MI United States

2.12miles

View all locations

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Brief description of study

Novartis Investigative Site

Volunteer Sign-up